News
-
Academia and industry join forces against malariaProfessor Leann Tilley and Dr Stanley Xie from the Bio21 Institute are working with experts from the Japanese company, Takeda Pharmaceuticals, and Swiss-based foundation, Medicines for Malaria Venture (MMV), in a double-pronged effort to develop new antimalarial drugs.
-
$14m invested to create vaccine for debilitating periodontal gum diseaseMelbourne Dental School Head of School Mike Morgan, CSL Senior Vice President of Research Andrew Nash, University of Melbourne Vice-President (Enterprise) Doron Ben-Meir, COHR CEO & Director of Research Eric Reynolds, Member for Higgins Katie Allen and Brandon Capital Investment Manager Ingmar Wahlqvist at the launch of Denteric.
-
Media Release: A sweet solution for a persistent parasiteNew research was published today [Cell Host and Microbe, 11 September] that shows how an important group of human pathogens cause disease, opening up fresh avenues for much needed therapies.
-
NHMRC funds Bio21 structural biology and drug development researchCongratulations to Bio21's Leann Tilley and David Ascher, who have received NHMRC Development and Investigator grants respectively.
-
New Microscope installed in Department of Biochemistry @Bio21An exciting new microscope has been installed in the Biochemistry and Molecular Biology Node of the Biological Optical Microscopy Platform at the Bio21 Institute, 28 August 2019.
-
Women of Bio21 - Justine MinternRead about Justine Mintern, Biochemistry and Molecular Biology, Head of Vaccine Biology Lab
-
Media Release: CSL to Move Global Headquarters to Parkville Biomedical PrecinctMajor landmark development will significantly increase CSL’s presence in the Parkville biomedical precinct and cement Melbourne’s place as a world-class research destination
-
CryoEM insights into the nanomachine that powers the cell’s garbage disposal systemCapitalising on the revolution brought about by structural cryo-electron microscopy (cryo-EM), a Bio21 team led by Dr Mike Griffin and Prof Leann Tilley has generated molecular movies of a sophisticated nano-machine, called the proteasome.
-
Professor Karen Day receives US$3 million NIH funding to pursue world-leading malaria researchProfessor Karen Day has secured almost US$3 million funding from the NIH to further her world-leading malaria research at the Bio21 Institute.
-
Pursuit: Using bacteria to control mosquitoesRead Bio21's Ary Hoffmann's piece published in Pursuit about how the Wolbachia bateria may hold the key to controlling the spread of dengue fever, the Zika virus and other mosquito-borne diseases.
